Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 12 » default
Blood and Lymphatic Cancer: Targets and Therapy
ISSN: 1179-9889
- View all (103)
- Volume 14, 2024 (2)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Archive: Volume 12, 2022
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
Blackmon A, Aldoss I, Ball BJ
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:137-147
Published Date: 6 September 2022
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo MJ, Joseph JJ, Phan LM, DeStefano CB
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:119-136
Published Date: 29 August 2022
Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice
Cingam S, Sidana S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:107-117
Published Date: 18 August 2022
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:99-106
Published Date: 4 August 2022
Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
St-Pierre F, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:81-98
Published Date: 22 July 2022
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
Juluri KR, Siu C, Cassaday RD
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:55-79
Published Date: 30 May 2022
Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
Wang J, Alhaj Moustafa M, Kuhlman JJ, Seegobin K, Jiang L, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:47-54
Published Date: 25 May 2022
HIV/AIDS Associated Lymphoma: Review
Berhan A, Bayleyegn B, Getaneh Z
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:31-45
Published Date: 29 April 2022
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:23-29
Published Date: 14 April 2022
Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation
Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:17-21
Published Date: 23 March 2022
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Hein K, Short N, Jabbour E, Yilmaz M
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:7-16
Published Date: 19 March 2022
How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
Guru Murthy GS
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:1-6
Published Date: 19 March 2022